Can-Fite Biopharma rises as liver disease drug shows potential as obesity treatment

Can Fite Biopharma

20/12/2023 13:29

** U.S.-listed shares of Israeli drug developer Can-Fite
Biopharma  CANF.TA   CANF.N  rise 11.1% to $2.3 premarket
    ** Co says experimental drug namodenoson reduced body weight
in animals in preclinical trials 
    ** In a prior mid-stage clinical study evaluating
namodenoson as a potential treatment for a type of fatty liver
disease, it reduced body weight by 2.1% after 3 months in humans
     ** The data, along with the safety profile of namodenoson
in humans, serve as support for its potential development as an
anti-obesity drug - CANF
    ** The drug is currently being developed as a treatment for
fatty liver disease, nonalcoholic steatohepatitis (NASH), liver
cancer and pancreatic cancer
    ** Up to Tuesday's close, stock down 66.2% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))